- Record: found
- Abstract: not found
- Article: not found
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Pietro Perini, Sara Redaelli, M Marega, Frank Boschelli, R Rostagno, Vera Magistroni, Rocco Piazza, Carlo Gambacorti-Passerini
2009-01-20
Aniline Compounds, therapeutic use, Antineoplastic Agents, Benzamides, Drug Resistance, Neoplasm, Genes, abl, genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Mutation, Nitriles, Philadelphia Chromosome, Piperazines, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Pyrimidines, Quinolines, Thiazoles
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
Aniline Compounds,therapeutic use,Antineoplastic Agents,Benzamides,Drug Resistance, Neoplasm,Genes, abl,genetics,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,drug therapy,Mutation,Nitriles,Philadelphia Chromosome,Piperazines,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Protein Kinase Inhibitors,Pyrimidines,Quinolines,Thiazoles
Aniline Compounds, therapeutic use, Antineoplastic Agents, Benzamides, Drug Resistance, Neoplasm, Genes, abl, genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Mutation, Nitriles, Philadelphia Chromosome, Piperazines, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Pyrimidines, Quinolines, Thiazoles